Holen Sie sich die Stockscreener-App
0.342
14.77%
0.044
Vorhandelsmarkt:
.34
-0.002
-0.58%
Schlusskurs vom Vortag:
$0.298
Offen:
$0.298
24-Stunden-Volumen:
1.60M
Relative Volume:
2.35
Marktkapitalisierung:
$31.76M
Einnahmen:
$1.22M
Nettoeinkommen (Verlust:
$-14.15M
KGV:
-1.3154
EPS:
-0.26
Netto-Cashflow:
$-6.55M
1W Leistung:
+13.25%
1M Leistung:
-10.89%
6M Leistung:
+10.61%
1J Leistung:
-8.06%
1-Tages-Spanne:
$0.298
$0.358
1-Wochen-Bereich:
$0.2839
$0.358
52-Wochen-Spanne:
$0.2525
$0.4985
IGC Pharma Inc Stock (IGC) Company Profile
Firmenname
IGC Pharma Inc
Sektor
Branche
Telefon
301-983-0998
Adresse
4336 Montgomery Avenue, Bethesda, MD
Vergleichen Sie IGC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.342 | 27.67M | 1.22M | -14.15M | -6.55M | -0.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
IGC Pharma Inc Aktie (IGC) Neueste Nachrichten
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." - Digital Journal
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We - pharmiweb.com
IGC Pharma Achieves 65% Enrollment In Phase 2 CALMA Trial For Alzheimer's Agitation - Nasdaq
Ascendiant Capital Markets Issues Positive Forecast for IGC Pharma (NYSEMKT:IGC) Stock Price - Defense World
Ascendiant Capital Maintains IGC Pharma (IGC) Buy Recommendation - Nasdaq
IGC Pharma (IGC): Ascendiant Capital Raises Price Target to $4.7 - GuruFocus
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 C - GuruFocus
IGC Achieves Significant Enrollment Progress in Phase 2 Alzheimer's Trial - GuruFocus
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial - pharmiweb.com
Can IGC Pharma Inc. stock test all time highsEarnings Recap Report & Fast Gaining Stock Reports - Newser
Why IGC Pharma Inc. (IGS1) stock is favored by hedge fundsQuarterly Performance Summary & Fast Moving Trade Plans - Newser
Why institutional investors increase stakes in IGC Pharma Inc. (IGS1) stockInflation Watch & Fast Entry Momentum Alerts - Newser
Why IGC Pharma Inc. (IGS1) stock attracts HNW investorsBuy Signal & Weekly Breakout Watchlists - Newser
Is IGC Pharma Inc. (IGS1) stock worth holding before Fed meeting2025 Price Action Summary & Low Risk Entry Point Tips - Newser
IGC Pharma (NYSE American: IGC) registers 978,235 shares for stockholder resale - Stock Titan
Is IGC Pharma Inc. (IGS1) stock a top pick for value investorsJuly 2025 Review & Weekly Watchlist for Consistent Profits - Newser
Is IGC Pharma Inc. stock worth holding before Fed meetingWeekly Trend Recap & Capital Efficiency Focused Ideas - Newser
Will IGC Pharma Inc. stock beat value stocksGDP Growth & Safe Capital Growth Plans - Newser
IGC Pharma Publishes Caregiver's Guide on Alzheimer's Disease - GuruFocus
IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease - Big News Network.com
Why IGC Pharma Inc. stock stays undervaluedMarket Volume Summary & Expert Curated Trade Setups - Newser
Will IGC Pharma Inc. (IGS1) stock beat growth indexesShare Buyback & Verified Trade Idea Suggestions - Newser
How IGC Pharma Inc. stock reacts to weak economyWeekly Risk Summary & Reliable Volume Spike Trade Alerts - Newser
What drives IGC Pharma Inc stock pricePortfolio Allocation Tips & Buy Sell Signal Notifications - earlytimes.in
New Strong Buy Stocks for Oct. 24: IGC, ASM and More - MSN
IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Fact - GuruFocus
IGC Pharma (IGC) Advances Alzheimer's Research with AI-Driven Ap - GuruFocus
IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Tr - PharmiWeb.com
IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends - Weatherford Democrat
IGC Pharma (NYSE: IGC) Uses MINT-AD AI to Map Socioeconomic Alzheimer’s Risks - Stock Titan
An analyst sees good growth prospects for IGC Pharma Inc (IGC) - Setenews
Will IGC Pharma Inc. stock benefit from AI adoption2025 EndofYear Setup & Intraday High Probability Alerts - newser.com
Is IGC Pharma Inc. (IGS1) stock considered safe havenEarnings Summary Report & AI Forecast Swing Trade Picks - newser.com
Is IGC Pharma Inc. (IGS1) stock undervalued after correction2025 Market Overview & Technical Pattern Based Signals - newser.com
Is IGC Pharma Inc. stock a contrarian opportunityWeekly Gains Report & Risk Controlled Swing Alerts - newser.com
How IGC Pharma Inc. stock responds to job market shiftsJuly 2025 Market Mood & Safe Entry Point Alerts - newser.com
Finanzdaten der IGC Pharma Inc-Aktie (IGC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):